randombio.com | Science Dies in Unblogginess | Believe All Science | I Am the Science
Sunday, October 04, 2026 | science | neurology

Sodium bicarbonate prevents Alzheimer’s disease? Not so fast

Put down the vinegar and baking soda and put away that plunger


A new paper in eBioMedicine claims that sodium bicarbonate, aka baking soda, reduces the risk of dementia by 51%. [1]

The authors correlated a variety of drug treatments given to patients with the onset of Alzheimer’s disease and related dementias, or ADRD, which includes vascular dementia but typically mostly means AD (Alzheimer’s disease) itself.

Even though eBioMedicine is a Lancet journal, this is a reasonably good paper. It was an observational study from a large database. This means they had a large N (24,855 with ADRD). However, 57% of the groups had some imbalance, the specific type of dementia was not broken out, and the results are only statistical correlations. The 24,855 patients were spread across 181 drugs, so on average it would be 137.3 dementia patients per drug, plus a lot more controls without dementia. To make it more convincing, we would also need two more things: A biochemical mechanism to explain what the drugs are doing and a placebo-controlled clinical trial to show cause-and-effect.

Vinegar and baking soda

Vinegar and baking soda, not necessarily a treatment for dementia

Querying large databases is how a lot of research is done these days. If you propose doing MRIs, for example, they won’t fund you. They’ll say there’s a big MRI database out there, just use that. You can’t compete; as with a GWAS (genome-wide association study), you get a bigger N in a database than your lab could ever afford. If your question is not in the database, that’s too bad. It’s a roundabout way of saying they think there’s nothing new to discover and science is now just filling in the gaps.

Most people think of sodium bicarbonate as something you pour down the sink with vinegar in the belief that it will unclog your drain. That’s obviously probably not what it’s doing here, but there is still ambiguity: Is it the sodium or the bicarbonate that is having an effect?

Baking soda is different from washing soda, which is sodium carbonate; and Bon Ami, which is calcium carbonate. Ingesting either of them would be very harmful. All drugs have side effects, sometimes lethal ones, so just taking one or more of the drugs in this study out of hope would be a very bad idea.

Repurposing

Drug repurposing is a way of skipping the expensive clinical drug trials and lengthy FDA approval process. It is sometimes risky and often leads researchers down the garden path. If it works, it can bring a lifesaving drug to patients much quicker. The repurposing of gabapentin as an anti-pain drug is an example.

The findings

The authors used the Benjamini-Hochberg procedure to control the false discovery rate. This is an essential step because testing large numbers of hypotheses always leads to spurious correlations.

The main finding is that 20 drugs seemed to dramatically reduce the incidence of dementia by about 50%. They are:

So what we have here is the pharmacological equivalent of a GWAS. The authors try to justify how the drugs might work, but they can only speculate. That’s the best we’re likely to get these days now that NIH has practically stopped funding basic research on Alzheimer’s disease.

A weakness of the study is that they don’t name the drugs that did not work, so it’s hard to evaluate the results. We need to see the confidence intervals and statistics for those 161 other drugs. Suppose, for instance, celecoxib works but aspirin doesn’t. That would hint that it’s a side effect and not COX-2 inhibition by itself. Now somebody else has to test them both to find out.

Alternative interpretations

The subjects were patients who were given the drug as part of their treatment for something else. So if the results are true, it could mean one of three things:

  1. Those conditions (inflammation, pain, bacteria, acid-base imbalance, etc.) are potential risk factors for dementia because treating them prevented dementia.

  2. The drug worked, but its effect on dementia was an unexpected side effect.

  3. The diseases themselves actually protect against dementia and the treatment was just a ‘witness’.

This last one is not so far-fetched as it sounds. Cancer is known to prevent Alzheimer's disease. Whether it is the treatment that patients receive, the immune response to the disease, the fact that cancer treatment can cause immunodeficiency, or, as many people think, there is an inherent imbalance between cell growth and cell senescence, is not known.

These results don’t say eating bicarbonate of soda will prevent dementia. At best it’s a clue that dementia patients might have some metabolic condition that upsets their acid-base balance. Or the disorder could prevent absorption of some essential nutrient. If so, the drugs don’t necessarily have to cross the blood-brain barrier to work.

Some of the drugs on the author’s list have been tested already on AD and found to have no effect. For instance, celecoxib failed in clinical trials years ago and results with prednisone were not encouraging. Steroids can cause psychiatric symptoms in Alzheimer patients. Gabapentin was found to increase the odds of ADRD in another observational study. Pregabalin was already tested in a clinical trial for treating behavioral symptoms in AD, and estradiol has been tested repeatedly. These points should have been brought up in peer review.

In the author’s defense, it’s hard to find a list of AD drugs that failed in clinical trials other than by going through the list of 4260 AD trials at clinicaltrials.gov. M.A.S. Guth compiled a partial list [2]. For some odd reason, the news media only mention one: Ramaswamy’s failed trial of the 5HTR6 antagonist intepirdine.

The observation made elsewhere that people with gingivitis have a higher incidence of AD is a good example of the need to separate cause and effect. Does bacterial inflammation cause dementia, or do people with dementia forget to brush their teeth? Nobody knows.

Another potential issue is immortal time bias, where only patients who do not have a bad outcome (i.e., are ‘immortal’ during the period between two events) are included in the study, thus biasing the study in favor of patients with a good prognosis.

Bicarbonate for AD is not as far-fetched as it sounds. One clinical trial is testing xenon gas. But the same criticism of GWAS studies applies here: if the authors really believed their findings, they’d be following up on them themselves.


[1] Wu Q, Li L, Lei Y, Zhou T, Tang H, Zhang B, Lu Y, Salvatore M, Zhang D, Tong J, Wang T, Chen S, Li H, Xu Z, Huang Y, Hu Y, Hong N, Zhou Y, Lin F, O'Brien KS, Chen Y, Li R, Xu H, Wang F, Bian J, Wolk DA, Chen Y. Discovering repurposable drugs for Alzheimer's disease and related dementias: target trial emulation using decentralised real-world data. EBioMedicine. 2026 Sep 4;132:106466. doi: 10.1016/j.ebiom.2026.106466. PMID: 42697072; PMCID: PMC13572180.

[2] Guth MAS. The highest clinical trial failure rate for any disease in modern medicine: How both amyloid- and non-amyloid-targeting therapies failed to alter disease course in Alzheimer's disease. Free Neuropathol. 2026 Aug 27;7:22. doi: 10.17879/freeneuropathology-2026-9650. PMID: 42683436; PMCID: PMC13532280.

oct 04 2026, 6:38 am. updated oct 05 2026, 5:18 am


Related Articles

Are there really 345 risk genes for neuropsychiatric disorders?
Misleading genome-wide association studies are finding mostly noise

What we need to know about ivermectin and cancer
Ivermectin is being repurposed for cancer. What is repurposing, and why is it risky?

Cancer and Alzheimer researchers are working at cross purposes
The bad protein theory is not only nonsensical, it's preventing people from curing diseases

Does lithium deficiency cause Alzheimer's disease?
There's evidence for some environmental factor, maybe even a metal, but the case for lithium is mostly circumstantial

Is Alzheimer's disease caused by a fungus?
A possible new direction in view of the failures of antiamyloid therapy.


Fippler

back
science
technology
home